SubsidieMeestersGreen Laser-Assisted Surface Structuring
Biomimetic aims to enhance the mechanical durability of its innovative GLASS laser process for producing antireflective nanostructured glass, targeting consumer electronics and specialized optics markets.
Projectdetails
Introduction
Biomimetic (BIOM), a spin-off of the Foundation for Research and Technology-Hellas (GR), was founded in 2020 to lead the exploitation of the results coming from a long R&D pathway on developing laser strategies for producing bionic surfaces. This includes projects such as LiNaBioFluid and Biocombs4Nanofibers FET.
GLASS Technology
One of these investigations led to GLASS, a novel, cost-effective laser process capable of imprinting biomimetic antireflective (AR) nanostructures on glass.
Advantages of GLASS
GLASS provides remarkable AR properties using a single-step and environmentally friendly manufacturing process. This is in contrast to the most commonly used AR coating techniques in the industry, which involve the use of chemicals and multiple steps.
Commercial Applications
Considering the huge commercial applications that this unique laser strategy can have, such as:
- Displays
- Special optics
- Digital cameras
- Automotive
- Telecommunication
- Solar systems
With this project, BIOM will funnel efforts to address the major challenge of GLASS related to the mechanical durability of laser-treated glass.
Project Goals
The ultimate aim is the use of GLASS-produced AR glass for small-scale commercial applications, with an emphasis on consumer electronics displays and specialized optics markets.
Partnerships
For this purpose, BIOM is partnering with Corning Inc (CORN), currently the leading glass manufacturer for consumer electronics. Together, they will work on optimizing the GLASS process to meet the mechanical durability specifications of the two respective markets.
Collaboration with LASEA
At the same time, BIOM will co-develop an automated GLASS laser system with LASEA, a recognized laser systems manufacturer. These technical improvements will be validated by CORN, who will undertake the role of customer.
Support from FORTH PRAXI NETWORK
BIOM will receive support from FORTH PRAXI NETWORK, a highly specialized company in technology.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.498.945 |
| Totale projectbegroting | € 2.498.945 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- VIOMIMITIKI IDIOTIKI KEFALAIOUCHIKI ETAIREIApenvoerder
- CORNING SAS
- LASER ENGINEERING APPLICATIONS SA
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
New Horizons in Glass Structure Prediction and MechanicsNewGLASS aims to revolutionize glass design by integrating computational methods and machine learning to create novel glass compositions with enhanced fracture resistance for diverse applications. | ERC COG | € 1.996.935 | 2022 | Details |
Bioinspired composite architectures for responsive 4 dimensional photonicsBIO4D aims to create biomimetic 3D photonic structures using self-ordering nanomaterials and advanced fabrication to enable dynamic optical responses for various applications. | ERC STG | € 1.498.579 | 2023 | Details |
Unprecedented photolithographic structuring of novel light-sensitive poly(amino acid) materials– a paradigm shift in delivering biocompatible devicesPOLINA aims to revolutionize bioprinting and medical devices by combining innovative light-sensitive materials with advanced photolithography for improved tissue compatibility and drug discovery. | EIC Pathfinder | € 2.882.322 | 2024 | Details |
EVERGLASS: THE NEW ROLE OF GLASS IN A SUSTAINABLE SOCIETY. TECHNOLOGY FOR THE INTEGRAL RECYCLING OF GLASS.EverGLASS aims to revolutionize glass recycling with a new "glass laser transformation" technology for on-site, customizable recycling, significantly reducing carbon footprint and enhancing user participation. | EIC Pathfinder | € 2.961.225 | 2024 | Details |
New Horizons in Glass Structure Prediction and Mechanics
NewGLASS aims to revolutionize glass design by integrating computational methods and machine learning to create novel glass compositions with enhanced fracture resistance for diverse applications.
Bioinspired composite architectures for responsive 4 dimensional photonics
BIO4D aims to create biomimetic 3D photonic structures using self-ordering nanomaterials and advanced fabrication to enable dynamic optical responses for various applications.
Unprecedented photolithographic structuring of novel light-sensitive poly(amino acid) materials– a paradigm shift in delivering biocompatible devices
POLINA aims to revolutionize bioprinting and medical devices by combining innovative light-sensitive materials with advanced photolithography for improved tissue compatibility and drug discovery.
EVERGLASS: THE NEW ROLE OF GLASS IN A SUSTAINABLE SOCIETY. TECHNOLOGY FOR THE INTEGRAL RECYCLING OF GLASS.
EverGLASS aims to revolutionize glass recycling with a new "glass laser transformation" technology for on-site, customizable recycling, significantly reducing carbon footprint and enhancing user participation.